This segment focuses on the development and manufacturing of biosimilar drugs, leveraging Viropro's expertise in biopharmaceutical production. Research and development activities include cloning, sequencing, purifying, developing, validating, and producing biosimilar products for pre-clinical and clinical trials (Phase I, II, and III). The company utilizes mammalian cell protein production, including monoclonal antibodies and recombinant proteins. This segment addresses the growing demand for cost-effective alternatives to branded biologics, targeting diseases such as cancer, diabetes, hepatitis, and multiple sclerosis. Viropro's collaboration with Oncobiologics highlights its commitment to expanding its biosimilar pipeline and market reach, particularly in emerging markets. Future opportunities include expanding the portfolio of biosimilars and securing regulatory approvals in key markets.

Viropro provides comprehensive contract research and manufacturing services to biotech and biopharmaceutical companies. This segment encompasses a wide range of activities, including cloning, sequencing, purification, development, validation, and production of biopharmaceutical products and sub-products. The company offers services for pre-clinical and clinical trials, focusing on biologics drugs and mammalian cell proteins, such as monoclonal antibodies and recombinant proteins. Viropro's expertise in cell-derived products and its ability to supply mammalian cell proteins position it as a valuable partner for companies seeking to outsource their research and manufacturing needs. The company's operations in Canada, the United Kingdom, and Malaysia provide a global footprint for serving clients worldwide. Future growth potential lies in expanding its service offerings and securing additional contracts with biotech and biopharmaceutical companies.